The Life Sciences team advised Zafgen on its $20 million venture debt financing agreement with Silicon Valley Bank to add non-dilutive capital to its balance sheet and extend its expected cash runway beyond the first half of 2019.
Zafgen is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases.
The Goodwin team was led by partner included partners Mitchell Bloom and associate Shoaib Ghias.
For additional details on the agreement, please read the press release.
Zafgen is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases.
The Goodwin team was led by partner included partners Mitchell Bloom and associate Shoaib Ghias.
For additional details on the agreement, please read the press release.